NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) — Analysis Summary
NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) has a market cap of $2.53B with year-over-year revenue growth of -50.6%. Net margin stands at -905.7%. The stock trades at a P/E ratio of -9.8.
Key Takeaways
- Revenue changed -50.6% year-over-year
- Net margin of -905.7%
- P/E ratio of -9.8
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, NAMS posted revenue growth of -50.6% and trades at a P/E of -9.8.
NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Operating margin at -3432.2% — severe operating losses
Net margin at -3644.2% — losses exceed revenue (possible one-time charges)
Revenue fell 68.4% vs the prior period.
The latest filing shows negative free cash flow.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
100
Headquarters
NARRDEN, P7
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.